TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23277147

Group type: EXPERIMENTAL
Intervention: Salivary nitrate secretion after stress activity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salivary nitrite levels after stress activity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intragastric nitrate administration in BPSDL rats
Number of subjects: 22

Group type: COMPARATOR
Intervention: Gastric ulcer index (UI) in BPSDL rats
Number of subjects: 22
Study: 20132103

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1590
Study: 17522618

Group type: EXPERIMENTAL
Intervention: L-5-methyltetrahydrofolate (1 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Folic acid (1 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15860689

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise, 5 times per week for 60 minutes at moderate intensity (approximately 60% peak oxygen uptake)
Number of subjects: 24
Study: 14668077

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (subgroup analysis by genotype)
Number of subjects: 30
Study: 11123867

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary systemic chemotherapy
Number of subjects: 0
Study: 8833458

Group type: EXPERIMENTAL
Intervention: 0.02% cinnamic aldehyde in ethanol (patch test)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.1% cinnamic aldehyde in ethanol (use test)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patch test sensitivity
Number of subjects: 18
Study: 1424058

Group type: EXPERIMENTAL
Intervention: Unilens contact lens
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bi‐Tech contact lens
Number of subjects: 42
Study: 6740101

Group type: EXPERIMENTAL
Intervention: Oral trivalent poliovirus vaccine (OPV)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Injectable trivalent poliovirus vaccine (IPV)
Number of subjects: 439
Study: 31292644

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Low HDL
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemia
Number of subjects: 435
Study: 31527167

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 0
Study: 28255750

Group type: EXPERIMENTAL
Intervention: Basic self-monitoring app
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Basic app plus goal setting
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Basic app plus points-based feedback
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Basic app plus both modules (goal setting and points-based feedback)
Number of subjects: 116
Study: 25294560

Group type: EXPERIMENTAL
Intervention: direct MRI (dMRI) arthrography
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: indirect MRI (iMRI) arthrography
Number of subjects: 10
Study: 23968880

Group type: EXPERIMENTAL
Intervention: Resilient Families intervention (social relationship curriculum for students, parent education handbooks, and events)
Number of subjects: 2354

Group type: EXPERIMENTAL
Intervention: Resilient Families intervention
Number of subjects: 2354

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2354
Study: 20957379

Group type: EXPERIMENTAL
Intervention: Foetal fibronectin testing (fFN)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Preterm labour management without fFN
Number of subjects: 88
Study: 19844113

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.066 mg/kg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Historical controls (14 age-matched preterm SGA)
Number of subjects: 25
Study: 16150843

Group type: EXPERIMENTAL
Intervention: Longitudinal diastolic function indexes in diabetic subjects
Number of subjects: 21

Group type: COMPARATOR
Intervention: Longitudinal diastolic function indexes in nondiabetic controls
Number of subjects: 21
Study: 12873921

Group type: EXPERIMENTAL
Intervention: Sevoflurane (gradually decreasing concentration from 8% to clinical awakening)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sevoflurane (steady-state at 1 and 2 MAC)
Number of subjects: 33
Study: 10695417

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg TID for 2 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8942586

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) at a dose of 15 micrograms/kg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo lozenge/IV fentanyl
Number of subjects: 19
Study: 1821296

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 417

Group type: COMPARATOR
Intervention: No nicotine gum (control)
Number of subjects: 417
Study: 6798584

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6377878

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine plus a blinded nasogastric tube
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine plus nasogastric suction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nasogastric suction plus cimetidine placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Blinded nasogastric tube plus cimetidine placebo
Number of subjects: 45
Study: 30185428

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy‐Health Care (6-month home‐ and community‐based treatment)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Attention control group (weekly family supportive counseling for 6 months)
Number of subjects: 167
Study: 25831410

Group type: EXPERIMENTAL
Intervention: Wobble board rehabilitation (REH) for 4 weeks, 3 sessions per week of 5 repetitions
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention (CON)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Wobble board rehabilitation (REH)
Number of subjects: 34
Study: 24829969

Group type: EXPERIMENTAL
Intervention: Platform switching abutments
Number of subjects: 68

Group type: COMPARATOR
Intervention: Platform matching abutments
Number of subjects: 68
Study: 23117724

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting (PTAS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical treatment (aspirin 100mg plus clopidogrel 75 mg/d)
Number of subjects: 70
Study: 20975461

Group type: EXPERIMENTAL
Intervention: Propofol/paravertebral anesthesia‐analgesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sevoflurane/opioid
Number of subjects: 32
Study: 18370571

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (3.4 g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15728439

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg, one capsule/day for 6 weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (matching capsule for 6 weeks)
Number of subjects: 87
Study: 12971422

Group type: EXPERIMENTAL
Intervention: Plant sterols (2.3 g per day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 41
Study: 10550273

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice daily for a mean of 26 days (range 17-35 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 32
Study: 8941586

Group type: EXPERIMENTAL
Intervention: Haemodialysis with SPAN membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemodialysis with PS membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemodialysis (general)
Number of subjects: 0
Study: 1794921

Group type: EXPERIMENTAL
Intervention: Low dose of new medication
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose of new medication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elevated liver enzymes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal liver enzymes
Number of subjects: 60
Study: 6135635

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion at a constant rate of 250 μg/h from 22.00 h until 07.00 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control test (saline infusion)
Number of subjects: 7
Study: 31580005

Group type: EXPERIMENTAL
Intervention: Lowest dose resulting in 24-hour lasting purpura
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lowest dose resulting in vessel disappearance observed by dermoscope
Number of subjects: 56
Study: 29658440

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4 Hz)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 28
Study: 26878710

Group type: EXPERIMENTAL
Intervention: VD3-rCM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VD3-PS80
Number of subjects: 0

Group type: COMPARATOR
Intervention: VD3-free placebo yogurt
Number of subjects: 0
Study: 25249415

Group type: EXPERIMENTAL
Intervention: 6 g cinnamon twice a day for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study: 22251435

Group type: EXPERIMENTAL
Intervention: Infliximab induction therapy (5 or 10 mg/kg every 8 weeks beginning at week 14)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Infliximab treatment with CRP normalization (decrease from 0.5 mg/dL at baseline to < 0.5 mg/dL at week 14)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Infliximab treatment at week 14 with low CRP levels
Number of subjects: 212
Study: 21134045

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (24 U)
Number of subjects: 381

Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 381
Study: 17617517

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 3
Study: 15652906

Group type: EXPERIMENTAL
Intervention: 95% trichloroacetic acid (TCA) instillation into uterine cavity
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone analogue (1 month before procedure)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 95% TCA instillation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone analogue
Number of subjects: 90
Study: 14563391

Group type: EXPERIMENTAL
Intervention: Tin(II) chloride at concentrations of <0.5, 161, 264, and 529 mg/kg in 250 ml tomato juice
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tin migrated from packaging at concentrations of <0.5, 201, and 267 mg/kg in 250 ml tomato soup
Number of subjects: 44
Study: 10397651

Group type: EXPERIMENTAL
Intervention: HA-coated TPS implants
Number of subjects: 65

Group type: COMPARATOR
Intervention: TPS cylinder implants
Number of subjects: 65
Study: 7740821

Group type: EXPERIMENTAL
Intervention: Peer education intervention using a sun protection curriculum
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group (no peer education)
Number of subjects: 508
Study: 2202538

Group type: EXPERIMENTAL
Intervention: Immediate ultrasound examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective ultrasound examination (control)
Number of subjects: 0
Study: 7270871

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0
Study: 30785357

Group type: EXPERIMENTAL
Intervention: MMR-RIT (Priorix, GSK)
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: MMR-RIT with DTaP-IPV and VV
Number of subjects: 4011

Group type: COMPARATOR
Intervention: MMR-RIT and MMR II
Number of subjects: 4011
Study: 28704492

Group type: EXPERIMENTAL
Intervention: Pretreatment MMP9 levels in CSF (median [interquartile range], 254 [115‐389] ng/mL in good outcome group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pretreatment MMP9 levels in CSF (median [interquartile range], 192 [60‐383] ng/mL in poor outcome group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CSF glucose levels correlation with MMP9 levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Admission Glasgow coma scale score correlation with MMP9 levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TIMP1 levels in CSF (1239 [889‐1511] ng/mL in good outcome group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TIMP1 levels in CSF (1522 [934‐1949] ng/mL in poor outcome group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MMP9/TIMP1 ratio (0.191 [0.107‐0.250] in good outcome group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MMP9/TIMP1 ratio (0.163 [0.067‐0.34] in poor outcome group)
Number of subjects: 40
Study: 24711613

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS), 1-Hz, right prefrontal, for 4 weeks.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER, for 4 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of predictive efficacy between rTMS and venlafaxine ER.
Number of subjects: 50
Study: 23584289

Group type: EXPERIMENTAL
Intervention: DE plus placebo (DEP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DE with N-acetylcysteine supplementation (DEN)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered air plus placebo (FAP)
Number of subjects: 13
Study: 21721593

Group type: EXPERIMENTAL
Intervention: E(2)V/DNG
Number of subjects: 58

Group type: COMPARATOR
Intervention: EE/LNG
Number of subjects: 58
Study: 19170687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16799877

Group type: EXPERIMENTAL
Intervention: Niobium stent (VELA STF)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bare metal stent (Antares STF)
Number of subjects: 65
Study: 15178172

Group type: EXPERIMENTAL
Intervention: Basic oculomotor tasks (overlap task)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exploratory tasks (everyday scenes and search task)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exploratory tasks (search task)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (16 healthy volunteers)
Number of subjects: 8
Study: 11141871

Group type: EXPERIMENTAL
Intervention: Group 1 (education with interviews)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group 2 (interviews only)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Group 3 (one interview only, control)
Number of subjects: 105
Study: 9170774

Group type: EXPERIMENTAL
Intervention: Intervention based on social cognitive theory
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intervention based on the theory of gender and power
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 90
Study: 8224655

Group type: EXPERIMENTAL
Intervention: Propranolol (continuous administration to reduce resting heart rate by 25%)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sclerotherapy (weekly intravariceal sessions using 5% ethanolamide oleate until varices disappeared)
Number of subjects: 116
Study: 3809993

Group type: EXPERIMENTAL
Intervention: Hemoccult‐II screening with written invitations and prestamped envelopes
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Colonoscopy following positive tests
Number of subjects: 60000
Study: 30227246

Group type: EXPERIMENTAL
Intervention: Enhanced education (educational pamphlets and videos for adults, including a 3-minute informational video on screening day)
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Standard education (no additional educational materials provided)
Number of subjects: 1243
Study: 26998789

Group type: EXPERIMENTAL
Intervention: STARTS (enhanced cognitive behavioral intervention)
Number of subjects: 300

Group type: COMPARATOR
Intervention: SUPPORT (supportive, time and attention-controlled comparison)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both STARTS and SUPPORT
Number of subjects: 300
Study: 26881516

Group type: COMPARATOR
Intervention: Conventional radiotherapy with cisplatin (Arm A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Concomitant boost therapy with cisplatin (Arm B)
Number of subjects: 60
Study: 23334177

Group type: EXPERIMENTAL
Intervention: Diode laser + mitomycin C + silicone intubation (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diode laser + silicone intubation (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diode laser + mitomycin C (Group 3)
Number of subjects: 80
Study: 21859919

Group type: EXPERIMENTAL
Intervention: Pain information booklet and instruction on infant comforting techniques
Number of subjects: 169

Group type: COMPARATOR
Intervention: Generic NICU care booklet alone
Number of subjects: 169
Study: 19081394

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 16870801

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation as an adjunct to standard pharmacotherapy
Number of subjects: 0
Study: 15295717

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg + Lisinopril 20 mg
Number of subjects: 23
Study: 11738913

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3% and dexamethasone 0.1% eyedrops
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard formulation of betamethasone and neomycin eyedrops
Number of subjects: 61
Study: 15102426

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups (ibuprofen, paracetamol, placebo)
Number of subjects: 66
Study: 8124315

Group type: EXPERIMENTAL
Intervention: THINKable program (computer-assisted attention and memory retraining)
Number of subjects: 15
Study: 2680896

Group type: EXPERIMENTAL
Intervention: Metronidazole (2 g twice at an interval of two days)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo (inert but identical tablets)
Number of subjects: 241
Study: 940718

Group type: EXPERIMENTAL
Intervention: Trained mothers providing consistent and authentic history of a child's common medical problem during interviews.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluative feedback session after videotaped interviews.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of students who did not interview trained mothers or receive evaluative feedback.
Number of subjects: 0
Study: 31746218

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1551
Study: 28757232

Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Uplifting piece of their own choice
Number of subjects: 94

Group type: COMPARATOR
Intervention: Acoustic control stimulus (white noise)
Number of subjects: 94
Study: 26630643

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ER-niacin)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25424627

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 8578
Study: 22238470

Group type: EXPERIMENTAL
Intervention: Miltefosine (1.8‐2.5 mg/kg/d for 28 days; by mouth)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Meglumine antimoniate (20 mg Sb/kg/d for 20 days; intramuscular)
Number of subjects: 116
Study: 20921440

Group type: EXPERIMENTAL
Intervention: Perhexiline 100 mg (n=24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 46
Study: 18023436

Group type: EXPERIMENTAL
Intervention: Birefringent sperm selection
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional ICSI
Number of subjects: 112
Study: 16186274

Group type: EXPERIMENTAL
Intervention: Fasting insulin concentration
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HOMA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: McAuley's index
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fasting triglyceride concentration
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 51
Study: 12634666

Group type: EXPERIMENTAL
Intervention: Vaginal pH of 5.0 or greater
Number of subjects: 6838

Group type: EXPERIMENTAL
Intervention: Vaginal pH of 4.5 or greater and Gram stain score of 9 to 10
Number of subjects: 6838

Group type: COMPARATOR
Intervention: Vaginal pH of less than 4.4 or 4.7
Number of subjects: 6838
Study: 10618544

Group type: EXPERIMENTAL
Intervention: Engerix-B 10 microg vaccine (EB)
Number of subjects: 2255

Group type: COMPARATOR
Intervention: Recombivax-HB 2.5 microg (RB)
Number of subjects: 2255
Study: 9093239

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment and therapy for opportunistic infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-associated non-Hodgkin lymphomas treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-associated central nervous system lymphomas treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hodgkin's disease treatment in HIV-infected individuals
Number of subjects: 0
Study: 8292067

Group type: EXPERIMENTAL
Intervention: Enteric coated multiple-unit formulation (Diclo-Puren 50)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Single-unit dosage form (reference)
Number of subjects: 18
Study: 2880294

Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg per kilogram of body weight per day) with decongestant-antihistamine
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg per kilogram of body weight per day) without decongestant-antihistamine
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 30691293

Group type: EXPERIMENTAL
Intervention: Self-Compassion Scale Short Form (SCS-SF)
Number of subjects: 594